Identification of CNKSR1 as a biomarker for "cold" tumor microenvironment in lung adenocarcinoma: An integrative analysis based on a novel workflow
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.CNKSR1 is a novel biomarker for identifying immune-cold lung adenocarcinoma (LUAD) tumors. Its expression correlates with lower PD-L1 levels and reduced immune cell infiltration, offering new therapeutic strategies.
Area Of Science
- Oncology
- Immunology
- Genomics
Background
- Anti-PD1/PD-L1 therapies have transformed lung cancer treatment but are ineffective for a subset of lung adenocarcinoma (LUAD) patients, particularly those with immune-cold tumors.
- Identifying novel biomarkers is crucial to expand therapeutic options for LUAD patients unresponsive to current immunotherapies.
Purpose Of The Study
- To identify a novel biomarker for predicting response to anti-PD1/PD-L1 immunotherapy in immune-cold LUAD.
- To investigate the relationship between the novel biomarker, PD-L1 expression, and immune cell infiltration.
Main Methods
- Utilized LUAD RNA-seq data from The Cancer Genome Atlas (TCGA) and applied machine learning to identify a candidate biomarker.
- Analyzed immune cell infiltration using ESTIMATE, ssGSEA, and CIBERSORT algorithms.
- Validated findings in independent datasets and performed immunohistochemistry (IHC) for CNKSR1, PD-L1, and CD8+ T cell infiltration.
Main Results
- CNKSR1 was identified as a promising biomarker for immune-cold LUAD, showing a negative correlation with PD-L1 expression and immune cell infiltration.
- CNKSR1 exhibited a mutually exclusive expression pattern with other immune checkpoint molecules.
- High CNKSR1 expression, coupled with low PD-L1, was associated with reduced CD8+ T cell infiltration.
Conclusions
- CNKSR1 serves as a potential biomarker for immune-cold LUAD, guiding therapeutic strategies.
- Further research into CNKSR1's role in T-cell modulation could uncover new targets to enhance LUAD immunotherapy effectiveness.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...